Memantina Aurobindo

Memantine Hydrochloride, the active ingredient in Memantina Aurobindo, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is used to treat moderate to severe Alzheimer’s disease in adult patients. GNH USA supplies Memantina Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantina Aurobindo is an NMDA‑receptor antagonist indicated for neurodegenerative conditions affecting cognition. - Alzheimer’s disease (moderate to severe): helps maintain cognitive function and daily living abilities. - Alzheimer’s disease (moderate to severe): may slow the rate of functional decline. - Alzheimer’s disease (moderate to severe): can improve behavioral symptoms such as agitation.

Memantina Aurobindo may cause a range of adverse reactions.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Fatigue: feeling unusually tired.

Serious or Rare Side Effects: - Seizures: new‑onset convulsive episodes. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: elevated liver enzymes or jaundice.

Before initiating therapy, clinicians should consider several safety factors. - Renal impairment: adjust dose or monitor renal function. - Hepatic impairment: use with caution in patients with liver disease. - History of seizures: assess risk of seizure exacerbation. - Concomitant NMDA antagonists: avoid additive neurotoxicity. - Blood pressure monitoring: watch for hypertension. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantina Aurobindo can interact with other medicines that affect the central nervous system or NMDA pathways.

Major Interactions (Avoid): - Amantadine: increased risk of neurotoxic effects. - Ketamine: additive NMDA antagonism may cause profound CNS depression. - Other NMDA antagonists: heightened risk of confusion and sedation.

Moderate Interactions (Monitor Closely): - Anticholinergics: may diminish cognitive benefit. - Diuretics: can raise plasma memantine concentrations. - CNS depressants (e.g., benzodiazepines): may enhance sedation.